KBC Group’s Catalyst Pharmaceutical CPRX Stock Holding History

KBC Group’s Portfolio CPRX Stock Details CPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$121K	Buy	4,887 +1,500	+44%	+$35.7K	﹤0.01%	1211
2025 Q4	$79K	Hold	3,387	–	–	﹤0.01%	1431
2025 Q3	$67K	Hold	3,387	–	–	﹤0.01%	1510
2025 Q2	$73K	Sell	3,387 -1,312	-28%	-$31K	﹤0.01%	1406
2025 Q1	$114K	Hold	4,699	–	–	﹤0.01%	1407
2024 Q4	$98K	Buy	4,699 +1,542	+49%	+$33.1K	﹤0.01%	1564
2024 Q3	$63K	Hold	3,157	–	–	﹤0.01%	1593
2024 Q2	$49K	Hold	3,157	–	–	﹤0.01%	1631
2024 Q1	$50K	Hold	3,157	–	–	﹤0.01%	1557
2023 Q4	$53K	Sell	3,157 -518	-14%	-$7.08K	﹤0.01%	1481
2023 Q3	$43K	Sell	3,675 -3,929	-52%	-$52.6K	﹤0.01%	1561
2023 Q2	$102K	Sell	7,604 -625	-8%	-$8.99K	﹤0.01%	1173
2023 Q1	$136K	Hold	8,229	–	–	﹤0.01%	1098
2022 Q4	$153K	Hold	8,229	–	–	﹤0.01%	1055
2022 Q3	$106K	Buy	+8,229	New	+$97.5K	﹤0.01%	1160

Other funds holding CPRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

KBC Group's CPRX Position: Q1 2026 in Review

KBC Group increased its Catalyst Pharmaceutical (CPRX) stake by 44% in Q1 2026, buying an estimated $35.7K and bringing the position to 4,887 shares worth $121K. The position accounts for ﹤0.01% of the portfolio, ranked #1211.

KBC Group first reported a position in CPRX in Q3 2022 and has held it in 15 quarters since. The position peaked at $153K in Q4 2022. 380 funds tracked by Wall St. Rank hold CPRX as of Q1 2026.

KBC Group held 4,887 shares of Catalyst Pharmaceutical worth $121K as of Q1 2026.
KBC Group bought 1,500 Catalyst Pharmaceutical shares in Q1 2026, an estimated $35.7K.
Catalyst Pharmaceutical made up ﹤0.01% of KBC Group's portfolio in Q1 2026, its #1211 holding.
KBC Group first reported a position in Catalyst Pharmaceutical in Q3 2022 and has held it in 15 quarters since.
KBC Group's Catalyst Pharmaceutical position peaked at $153K in Q4 2022.
380 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2026.

Based on KBC Group's 13F filing for Q1 2026, filed 7 May 2026.